Hims & Hers Health (NYSE:HIMS) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually-high trading volume on Friday . Approximately 5,570,696 shares were traded during trading, a decline of 38% from the previous session’s volume of 8,949,964 shares.The stock last traded at $25.99 and had previously closed at $27.94.

Analyst Ratings Changes

HIMS has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their target price for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Canaccord Genuity Group increased their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Finally, Morgan Stanley began coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Stock Performance

The company has a market capitalization of $6.07 billion, a P/E ratio of 63.19 and a beta of 1.31. The company’s fifty day simple moving average is $27.68 and its 200-day simple moving average is $21.85.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the firm earned ($0.04) earnings per share. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This represents a 1.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $22.20, for a total transaction of $166,500.00. Following the completion of the sale, the insider now owns 193,980 shares in the company, valued at $4,306,356. This represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,080,208 shares of company stock valued at $29,106,823. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. SG Americas Securities LLC grew its stake in Hims & Hers Health by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 104,422 shares of the company’s stock worth $2,525,000 after buying an additional 31,915 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after buying an additional 2,442 shares during the last quarter. Stonekeep Investments LLC increased its position in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares in the last quarter. Finally, Lake Street Private Wealth LLC raised its stake in Hims & Hers Health by 28.7% in the fourth quarter. Lake Street Private Wealth LLC now owns 133,168 shares of the company’s stock valued at $3,220,000 after buying an additional 29,721 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.